The Shkreli  controversy: the frightening power of pharmaceutical companies

Carol O’Brien reports on the story of the dramatic rise in Daraprim’s price by 5500% and describes the greed driven desire of pharmaceutical companies to make a profit at the cost of human health and life.

SCITECHWhen Turing Pharmaceuticals bought the rights to a little-known drug called Daraprim this past September, it didn’t take long for the story to sweep across social media, evoking a particularly fiery response. Immediately after buying Daraprim, Turing raised the price